Martin Shkreli Net Worth: What Is the “Pharma Bro” Really Worth in 2026?
Two websites can disagree about Martin Shkreli’s net worth by more than $100 million, and both can claim to be using real data. One lists him at zero. Another shows him above $100 million. The reason is that they measure different things: his peak wealth, a stale stock filing, or the result of court orders that took most of it away. The Martin Shkreli net worth cannot be reliably measured, and the most defensible baseline sits near zero or below. This guide explains where each estimate comes from, what the court records show, and what he is doing now.
Martin Shkreli at a Glance
| Detail | Information |
| Estimated Net Worth | Not reliably measurable, with published figures from $0 to over $100 million |
| Age | 43 (born March 17, 1983) |
| Birthplace | Brooklyn, New York |
| Known For | Raising the price of Daraprim by more than 5,000% and a 2017 securities fraud conviction |
| Current Ventures | DL Software (the company behind Godel Terminal) and an advisory role at Q/C Technologies |
| Last Updated | October 2026 |
Short Biography of Martin Shkreli
Martin Shkreli was born on March 17, 1983, in Brooklyn, New York. His parents were Albanian immigrants who worked as janitors, and he grew up in a working-class neighborhood with his siblings. He attended Hunter College High School but left before his senior year and finished his diploma at City As School High School, an alternative program in New York City.
His ambition showed early. At 17, he landed an internship at the hedge fund run by Jim Cramer, the CNBC host. He later attended Baruch College and graduated in 2004 with a bachelor’s degree in business administration. In March 2015, Hunter College High School announced that Shkreli had donated $1 million, the largest gift in the school’s history. He then built a career in hedge funds and biotech that ended in a federal conviction, and he is now barred from the pharmaceutical industry for life.
What Is Martin Shkreli’s Net Worth?
No verified figure exists for his net worth in 2026, and the numbers online contradict each other by more than $100 million. Celebrity Net Worth lists him at $0 and notes that his wealth peaked near $70 million before his 2015 arrest. Some securities databases, by contrast, still show him above $100 million.
The most realistic reading is that his financial position is close to zero or even negative. A $64.6 million court-ordered disgorgement, a lifetime ban from the pharmaceutical industry, and criminal forfeitures wiped out the fortune he built at Turing Pharmaceuticals. Since his release, the only verified income figure is a 2023 probation filing showing he earned $2,500 a month consulting for a law firm while living with his sister in Queens.
That does not mean he is finished financially. He holds equity in a software startup, an advisory arrangement with a publicly traded company, and an audience that earns money through livestreams and a newsletter. Those pieces are hard to value from the outside, so any single number attached to his name deserves skepticism.
Why Net Worth Estimates for Martin Shkreli Vary So Widely
Few public figures have estimates this scattered, and the gap comes from sources measuring different things.
| Source | Reported Figure | What Explains It |
| Celebrity Net Worth | $0 (peak of $70 million) | Accounts for forfeitures and legal judgments |
| GuruFocus | Over $100 million | Based on a 2014 stock filing that assumes he still owns the shares |
| Other aggregator sites | Roughly $27 million to $200 million | Methods are often unclear or unsourced |
His Peak Before the 2015 Arrest
His wealth peaked at roughly $70 million in 2015, and according to his own legal team, most of it came from his stake in Turing Pharmaceuticals. A court filing that surfaced after his December 2015 arrest gave a rare look at his finances. It showed that a brokerage account holding $45 million had been used to secure his $5 million bail bond. That period is the source of most of the large numbers still attached to his name, and everything after it, from the trial to the civil judgments, moved his finances in one direction.
Why Some Databases Still Show Him as Rich
The biggest outlier is GuruFocus, which lists his net worth at more than $106 million. Its method explains why that is misleading. GuruFocus builds the figure from SEC Form 4 filings, and its own disclaimer says the estimate assumes he made no transactions after November 21, 2014, and still holds the listed stock. The site attributes about 1.77 million shares of Travere Therapeutics, the company formerly known as Retrophin, to him.
Those shares belong to his past. Reporting on his case indicates that his Retrophin holdings, brokerage accounts, and other assets were sold or forfeited to cover his penalties. The number also changes daily with Travere’s stock price, even though Shkreli gains nothing from those moves. Automated wealth trackers rarely process forfeiture orders, so figures for convicted executives can stay frozen at pre-conviction levels for years.
How Forfeitures and Court Judgments Changed the Math
Three separate actions reshaped his balance sheet.
| Action | Amount | Source of Claim |
| Criminal forfeiture order | About $7.36 million | Federal criminal case |
| Civil disgorgement order over Daraprim | $64.6 million | Federal Trade Commission and state attorneys general |
| Tax warrant | $1.26 million | New York State, December 2016 |
Any headline claiming he is still a multimillionaire has to explain how his assets survived those claims, and most credible estimates treat near zero as the baseline for exactly that reason. A company’s trouble is also not the same as a founder’s personal bankruptcy, a point covered in our Dr Phil net worth guide, where the Merit Street Media case shows how corporate filings and personal finances can follow different paths. In Shkreli’s case, the claims were aimed at him personally, which is why they weigh so much more.
Early Finance Career and Hedge Funds
Shkreli’s early Wall Street career followed a pattern that repeated for years: bold bets, public confidence, and costly failures.
His internship at Cramer, Berkowitz, and Company turned into a four-year stint as an intern and associate. During that time, he recommended shorting Regeneron, a biotech company testing a weight loss drug. The stock fell as he predicted and the fund profited. The SEC took notice and looked into how he had made the call, but found no evidence of insider knowledge or wrongdoing.
After leaving, he worked as an analyst at two large investment banks before launching his own fund, Elea Capital Management, in 2006. It ran into trouble quickly. Lehman Brothers sued in 2007 after a losing short position left him unable to cover what he owed, and the bank won a $2.3 million judgment that October. Lehman collapsed before it could collect.
In 2009, he launched MSMB Capital Management, where his strategy was to short biotech companies and then discuss their weaknesses in online stock forums. Another failed bet followed. He shorted 32 million shares of a biotech company, the stock recovered, and he could not cover the position. Merrill Lynch lost about $7 million on the trade, and MSMB was effectively wiped out.
Hedge funds like these operate on a tiny scale next to the largest asset managers, and the biggest of them is covered in our BlackRock net worth guide, which shows how differently risk and size are handled at a global firm. Shkreli’s early funds show what happens when a single concentrated bet goes wrong without that kind of cushion.
Founding Retrophin
In 2011, Shkreli founded Retrophin, a biotech company focused on treatments for rare diseases. He served as CEO until the board removed him in the fall of 2014. Retrophin then filed a $65 million lawsuit against him, alleging stock trading irregularities and other securities violations. That period later became central to his criminal case.
Turing Pharmaceuticals and the Daraprim Price Hike
In February 2015, Shkreli founded Turing Pharmaceuticals, which acquired the rights to Daraprim later that year. The drug is a decades-old antiparasitic used to treat toxoplasmosis, a potentially life-threatening infection for people with weakened immune systems, including patients with AIDS.
Turing raised the price of Daraprim from $13.50 to $750 per pill, an increase of more than 5,000 percent. The move made him a national symbol of pharmaceutical greed and earned him the nicknames “Pharma Bro” and, in some coverage, “the most hated man in America.” In November 2015, the company announced it would not lower the price, and Shkreli hired lobbyists and a crisis public relations firm to defend the decision.
The controversy went beyond public anger. Congressional hearings followed, and a Federal Trade Commission antitrust case ultimately found that he had schemed to block generic competition. That case outlasted his criminal conviction and now shapes his finances more than any other event.
Arrest, Conviction, and Prison Sentence
Federal agents arrested Shkreli on December 17, 2015. The indictment did not involve Daraprim. Prosecutors charged him over his conduct at MSMB Capital and Retrophin, alleging that he misled investors about fund losses and used Retrophin assets to repay them.
At his 2017 trial, Shkreli argued that no investor lost money and that some made a profit. On August 4, 2017, the jury convicted him on two counts of securities fraud and one count of conspiracy to commit securities fraud, and acquitted him on five other counts. He was sentenced to seven years in federal prison on March 9, 2018, and an appeals court unanimously upheld the verdict in 2019.
His time in custody was not quiet. A federal judge revoked his bail after he offered his Facebook followers $5,000 to grab a strand of Hillary Clinton’s hair during her book tour. In 2019, the Bureau of Prisons investigated reports that he was running his pharmaceutical company from prison with a contraband cell phone. He served a little over four years, moved to a halfway house in May 2022, and was released from federal custody that September. His supervised release ended in 2025.
What Shkreli Lost: Forfeitures, Judgments, and Bans
His legal troubles did more than cost him his freedom. They stripped away nearly everything he had built.
The $7.36 Million Forfeiture and the Wu Tang Album
As part of his sentence, the judge ordered him to forfeit $5 million from his ETrade account and about $2.36 million in other assets, including a Pablo Picasso painting and a one of a kind Wu Tang Clan album. After legal defense fees, those were reportedly his remaining assets.
The album, Once Upon a Time in Shaolin, was pressed as a single physical copy. Shkreli won it at auction through Paddle8 on November 24, 2015, for $2 million. He later listed it on eBay, where it reportedly reached a bid of $1,025,100, but he was in custody before any sale could close, and the government seized it. According to reporting, the government sold the album in 2021 to the crypto collective PleasrDAO for $4 million.
The story did not end there. PleasrDAO sued Shkreli in June 2024 after he streamed the music to listeners and boasted online that he had kept copies of the files. In September 2025, a federal judge ruled that the album can qualify as a trade secret, allowing some of the claims to go forward. Shkreli filed a countersuit in early 2026. Whatever the result, the case adds legal costs and possible damages to a balance sheet with little room for either.
The $64.6 Million Disgorgement Order
The largest single hit came in January 2022, when a court ordered Shkreli to return $64.6 million in profits from the Daraprim price increase. The Supreme Court declined to hear his appeal in October 2024, making the debt final. The claim is held by the Federal Trade Commission and a group of state attorneys general, and it is larger than any assets he is publicly known to own.
The Lifetime Pharmaceutical Industry Ban
The same January 2022 ruling banned him from working in the pharmaceutical industry for life. It shut him out of the sector where he made his fortune, and it explains why his current ventures focus on software, market analysis, and areas outside drug pricing.
What Martin Shkreli Is Doing Now
Since his release, Shkreli has rebuilt a public career in three areas his bans do not cover: software, market commentary, and biotech analysis. A Bloomberg profile in July 2026 described him as back and unapologetic, shorting stocks and picking fights across the financial world. He also runs daily YouTube livestreams and a Substack newsletter, both of which earn income that no public filing measures.
| Venture | What It Is | Financial Detail |
| DL Software | Maker of Godel Terminal, a market data and analytics product | Raised a $2 million preseed round in July 2024 and a $5 million seed round in January 2026, valuation undisclosed |
| Q/C Technologies | Nasdaq-listed microcap developing light-based processors | Advisory deal reported at $12,500 per month, plus restricted shares and warrants |
| Livestreams and newsletter | Market commentary and short positions | Income not disclosed |
DL Software and Godel Terminal
His main venture is DL Software, which he founded in 2016 under the name Gödel Systems and revived after prison. Its flagship product, Godel Terminal, sells market data and analytics for $996 per year, positioned as a low-cost alternative to a Bloomberg Terminal seat that costs more than $30,000.
The company raised a $2 million preseed round in July 2024, led by dao5, Naval Ravikant, and Evolve Ventures. It then closed a $5 million seed round led by Infinitum in January 2026. DL also operates an AI health chatbot called Dr. Gupta and reports growing revenue, though those claims cannot be independently verified. His stake is probably his most credible asset, but it is illiquid and the company’s value has never been disclosed.
Q/C Technologies
In December 2025, Shkreli became a strategic advisor to Q/C Technologies. According to its SEC filing, the twelve-month agreement with an LLC linked to him pays $12,500 a month, or $150,000 a year. It also includes 212,500 restricted shares and warrants for another 212,500 shares at a $5.097 exercise price, with quarterly vesting conditions.
He published a bullish case for photonic computing in March 2026, arguing that optical chips could eventually challenge Nvidia in AI hardware. The company only moved from pharmaceuticals to photonics in late 2025 and carries heavy losses on minimal revenue, so his involvement looks more like a high risk equity bet than a stable income source.
Market Commentary and Short Positions
His most visible activity since prison is a public campaign of short positions, announced through his podcast, his account on X, and his livestreams. The platform where he posts is covered in our Twitter net worth guide, which explains how its ownership and value have changed since 2022. For a commentator like Shkreli, that reach is the product, since a large audience turns each post into a market event.
In December 2024, he disclosed a short on Strategy, formerly MicroStrategy, calling its leveraged Bitcoin accumulation a bubble. The trade hurt through 2025 as the stock climbed above $400. The 2026 crypto downturn reversed the scoreboard, with Bitcoin falling below $60,000 and Strategy hitting a two year low near $92 in June. His target list has also included IonQ and Quantum Computing Inc in 2024, Opendoor and Beyond Meat in 2025, and Sellas Life Sciences in mid 2026. None of his position sizes are public, so his actual profit or loss is guesswork.
The Pardon Application
In mid 2026, Shkreli formally applied for a presidential pardon, saying that talk of a mass clemency push tied to the country’s 250th anniversary prompted the filing. He says he paid no lobbyist and wants relief mainly so he can return to the pharmaceutical industry. President Trump has previously granted clemency to crypto figures such as Binance founder CZ and Ross Ulbricht, so the outcome is uncertain.
A pardon would not solve his biggest financial problems, though. It would address the criminal conviction, but the $64.6 million disgorgement and the lifetime industry ban are civil measures that fall outside the clemency power.
Personal Life
Shkreli’s personal life has been as public and provocative as his business career. In late 2015, he offered Kanye West $10 million, later raised to $15 million, for the album The Life of Pablo. During the 2016 election, he donated $2,700 to Bernie Sanders’ campaign, and in October 2016 he said he would either release or destroy the Wu Tang album depending on the election result. He shared a track the day after Donald Trump won.
In 2017, a judge allowed him to travel outside New York City while awaiting sentencing so he could speak at Harvard University. In May 2020, he asked the court to release him from prison so he could work on a coronavirus vaccine. Judge Kiyo Matsumoto denied the request, siding with probation officials who said the request reflected the same kind of behavior that had led to his sentence. According to a 2023 probation filing, he lives with his sister in Queens.
FAQs
What is Martin Shkreli’s net worth in 2026?
It cannot be reliably measured. Celebrity Net Worth lists $0 and notes a peak near $70 million, and the most defensible estimate is near zero or negative because of a $64.6 million judgment. Some databases show over $100 million, but that figure relies on outdated stock filings.
Is Martin Shkreli still rich?
Probably not by traditional measures. His known income since release is modest, and his largest potential assets are equity in DL Software and an advisory arrangement with Q/C Technologies, both hard to value. The $64.6 million claim against him is likely larger than anything he is known to own.
Why do some sites say he is worth over $100 million?
Databases such as GuruFocus calculate net worth from 2014 SEC filings that show him holding roughly 1.77 million Travere Therapeutics shares. The calculation assumes he never sold them, but those holdings were sold or forfeited years ago. The figure also shifts with Travere’s stock price, which has no link to his real finances.
What does Martin Shkreli do for a living now?
He runs DL Software, the company behind Godel Terminal, advises Q/C Technologies, and publishes market commentary through daily YouTube livestreams and a Substack newsletter. He is barred from the pharmaceutical industry for life.
How much did Martin Shkreli have to pay back?
A court ordered him to return $64.6 million in Daraprim profits in January 2022, and a separate criminal forfeiture order took about $7.36 million in assets, including $5 million from his ETrade account. New York State also issued a $1.26 million tax warrant against him in 2016.
Final Thoughts on the Martin Shkreli Net Worth
The Martin Shkreli net worth is a case where the headline figure depends entirely on what you choose to measure. His peak near $70 million is real but long gone, a $100 million database figure rests on a stale filing, and the court records point toward zero or below. What remains is a mix of a software startup, an advisory deal, and an online audience, none of which can be valued with confidence. Over the next year, the main things to watch are the PleasrDAO case, the pardon application, and whether Godel Terminal’s growth turns his equity into real money.
